Profile data is unavailable for this security.
About the company
Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across Latin America and Africa. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It has a portfolio across multiple therapeutic segments, stock & sell models, and supplies branded and generic medicines. The Company’s products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its subsidiary is Balaxi Global DMCC, Dubai.
- Revenue in INR (TTM)2.41bn
- Net income in INR-23.87m
- Incorporated1942
- Employees51.00
- LocationBalaxi Pharmaceuticals LtdPlot No: 409, 3rd Floor,Maps TowersJubilee Hills,Road No:81, HyderabadHYDERABAD 500096IndiaIND
- Phone+91 4 023555300
- Fax+91 4 023558085
- Websitehttps://balaxipharma.in/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Able View Global Inc | 12.43bn | 787.89m | 3.91bn | 98.00 | 5.02 | 4.16 | 4.85 | 0.3148 | 0.2229 | 0.2229 | 3.52 | 0.2695 | 2.72 | 6.20 | 8.37 | 1,520,406.00 | 17.80 | -- | 30.88 | -- | 24.84 | -- | 6.54 | -- | 1.99 | 7.90 | 0.2017 | -- | 2.58 | -- | 23.46 | -- | -- | -- |
Navamedic ASA | 4.07bn | 26.27m | 4.70bn | 45.00 | 179.97 | 2.65 | 38.81 | 1.15 | 0.1884 | 0.1884 | 29.75 | 12.82 | 1.13 | 3.39 | 6.24 | 11,377,690.00 | 0.7285 | 0.039 | 1.12 | 0.0635 | 38.88 | 38.33 | 0.6453 | 0.038 | 0.5543 | 1.85 | 0.4074 | -- | 33.98 | 22.72 | -88.77 | -2.53 | 59.60 | -- |
Kim Forest Enterprise Co Ltd | 1.07bn | -343.74m | 4.77bn | -- | -- | 3.28 | -- | 4.46 | -2.85 | -2.85 | 8.89 | 11.29 | 0.4986 | 3.34 | 4.31 | -- | -16.02 | -0.8245 | -19.78 | -1.06 | 13.15 | 31.99 | -32.14 | -1.25 | 1.19 | -82.43 | 0.2664 | -- | -38.11 | 12.36 | -341.58 | -- | -8.51 | -- |
Sinco Pharmaceuticals Holdings Ltd | 29.31bn | 488.62m | 5.10bn | 278.00 | 10.44 | 0.7037 | 7.56 | 0.174 | 0.0225 | 0.0225 | 1.35 | 0.334 | 1.53 | 22.60 | 5.73 | 9,876,659.00 | 2.56 | 6.48 | 6.55 | 20.22 | 12.73 | 14.79 | 1.67 | 3.86 | 1.08 | 28.20 | 0.2859 | 7.21 | 11.82 | 21.66 | -39.03 | -- | 123.63 | -- |
Hyphens Pharma International Ltd | 10.54bn | 529.15m | 5.25bn | 440.00 | 9.93 | 1.35 | 7.47 | 0.4984 | 0.0277 | 0.0277 | 0.5513 | 0.2037 | 1.45 | 4.65 | 4.89 | 387,715.90 | 7.29 | 8.35 | 12.10 | 14.01 | 36.29 | 37.06 | 5.03 | 5.65 | 1.35 | -- | 0.0939 | 33.00 | 5.10 | 7.12 | -24.52 | 9.63 | -18.70 | 9.35 |
Harima-Kyowa Co., LTD. | 32.67bn | 746.18m | 6.03bn | 197.00 | 7.98 | 0.4655 | 7.80 | 0.1847 | 261.75 | 261.75 | 11,459.40 | 4,490.24 | 1.91 | 23.79 | 5.51 | -- | 4.36 | 4.39 | 5.70 | 5.87 | 11.57 | 11.73 | 2.28 | 2.23 | 2.22 | -- | 0.0131 | 17.15 | 2.37 | 5.01 | 1.10 | 3.25 | 34.30 | 3.44 |
Balaxi Pharmaceuticals Ltd | 2.41bn | -23.87m | 6.57bn | 51.00 | -- | 3.22 | -- | 2.72 | -0.566 | -0.566 | 46.75 | 36.96 | 0.969 | 1.37 | 4.47 | -- | -0.9586 | 19.81 | -1.22 | 27.30 | 46.67 | 35.46 | -0.9893 | 11.95 | 2.36 | 26.61 | 0.0879 | -- | -28.28 | 77.76 | -105.19 | -- | 5.11 | -- |
Natural Health Trends Corp. | 3.59bn | 41.64m | 6.64bn | 138.00 | 159.11 | 2.02 | 122.06 | 1.85 | 0.0434 | 0.0434 | 3.75 | 3.42 | 0.582 | 2.24 | -- | 311,695.70 | 0.6751 | -0.5398 | 0.9333 | -0.7099 | 74.30 | 74.06 | 1.16 | -0.9571 | 2.77 | -- | 0.00 | -- | -10.60 | -25.54 | 81.47 | -54.86 | -26.47 | 6.64 |
111 Inc - ADR | 170.32bn | -4.32bn | 8.42bn | 1.52k | -- | -- | -- | 0.0495 | -0.6106 | -0.6106 | 24.07 | -1.04 | 4.80 | 9.62 | 32.62 | 1,342,754.00 | -10.93 | -17.09 | -- | -178.25 | 5.56 | 5.36 | -2.28 | -4.37 | 0.5234 | -19.99 | 0.4256 | -- | 10.59 | 52.95 | 5.80 | -- | -7.89 | -- |
Pharmaniaga Berhad | 60.36bn | -1.37bn | 9.20bn | 3.78k | -- | -- | -- | 0.1524 | -0.0572 | -0.0572 | 2.55 | -0.2056 | 1.82 | 4.59 | 9.57 | -- | -4.06 | -6.88 | -- | -38.45 | 9.04 | 6.64 | -2.23 | -3.66 | 0.2762 | 1.37 | 1.29 | -- | -3.02 | 7.38 | 87.25 | -- | 23.35 | -- |
Holder | Shares | % Held |
---|---|---|
Elara Capital Plc (Investment Management)as of 31 Mar 2023 | 950.00k | 8.72% |